Home > Insider Trading > Filing (0001209191-18-005829)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1566044	Menlo Therapeutics Inc.	MNLO	Pharmaceutical Preparations (2834)	453757789

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1618788	Vivo Capital Fund Viii, L.p.	505 Hamilton Ave, Suite 207 Palo Alto CA	No	No	Yes	No
1618789	Vivo Capital Viii, Llc	505 Hamilton Ave, Suite 207 Palo Alto CA	No	No	Yes	No
1628048	Vivo Capital Surplus Fund Viii, L.p.	C/O Vivo Capital Viii, Llc 505 Hamilton Ave, Suite 207 Palo Alto CA	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-01-25	258,432	$17.00	258,432	No	4	P	Indirect	By Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2018-01-25	35,686	$17.00	35,686	No	4	P	Indirect	By Vivo Capital Surplus Fund III, L.P.
Common Stock	Acquisiton	2018-01-29	2,348,550	$0.00	2,606,982	No	4	C	Indirect	By Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2018-01-29	324,306	$0.00	359,992	No	4	C	Indirect	By Vivo Capital Surplus Fund III, L.P.
Common Stock	Acquisiton	2018-01-29	917,559	$0.00	3,524,541	No	4	C	Indirect	By Vivo Capital Fund VIII, L.P.
Common Stock	Acquisiton	2018-01-29	126,703	$0.00	486,695	No	4	C	Indirect	By Vivo Capital Surplus Fund III, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Vivo Capital Fund VIII, L.P.
No	4	P	Indirect	By Vivo Capital Surplus Fund III, L.P.
No	4	C	Indirect	By Vivo Capital Fund VIII, L.P.
No	4	C	Indirect	By Vivo Capital Surplus Fund III, L.P.
No	4	C	Indirect	By Vivo Capital Fund VIII, L.P.
No	4	C	Indirect	By Vivo Capital Surplus Fund III, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2018-01-29	6,335,215	$0.00	2,348,550	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-01-29	874,817	$0.00	324,306	$0.00
Common Stock	Series C Preferred Stock	Disposition	2018-01-29	2,475,118	$0.00	917,559	$0.00
Common Stock	Series C Preferred Stock	Disposition	2018-01-29	341,784	$0.00	126,703	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Albert Cha, a director of the issuer, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.